Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
OPTHEA LIMITED (OPT)ASX AI Signals has generated 59 signals for OPT during the last 90 days, indicating strong trading activity and ongoing AI monitoring
Latest OPT Signals | |
| 25/06/2026 | BUY |
| 04/06/2026 | SELL |
| 03/06/2026 | BUY |
OPT Share Price | |
| Current Price | $0.014 |
| 52 Week High | $0.600 |
| 52 Week Low: | $0.013 |
| Trading at (% of 52 Week High) | 2.33% |
Opthea Limited (ASX: OPT) is a biopharmaceutical company focused on developing innovative therapies for eye diseases. The company specializes in treatments for wet age-related macular degeneration (AMD) and other retinal vascular diseases. Its lead product candidates target pathways involved in abnormal blood vessel growth and inflammation.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for OPTHEA LIMITED at the current low price of 0.0140 suggests potential upside, but the confidence is limited due to the stock's low price indicating possible volatility and liquidity concerns. Additional fundamental and technical data is needed to increase conviction.
Opthea Limited
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association’s Unit Opthea Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Opthea Limited
Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD hosted by Oppenheimer & Co.
MELBOURNE, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today  the resignation of Dr. Joel Naor, Chief Me Opthea Limited
MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul ThakralLatest OPTHEA LIMITED(OPT) News
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
Opthea to Present at the 2023 Ophthalmology Innovation Summit
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial